These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19506898)

  • 1. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
    Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ
    Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
    Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
    Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
    Giesel FL; Wulfert S; Zechmann CM; Haberkorn U; Kratochwil C; Flechsig P; Kuder T; Schwartz LH; Bruchertseifer F
    Exp Oncol; 2013 Jun; 35(2):122-6. PubMed ID: 23828389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
    Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraarterial Peptide Receptor Radionuclide Therapy Using
    Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
    J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
    Hung JS; Chang MC; Lee PH; Tien YW
    World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic endocrine tumor with neoplastic venous thrombus and bilobar liver metastasis. A case report.
    Barbier L; Turrini O; Sarran A; Delpero JR
    J Visc Surg; 2010 Feb; 147(1):e58-62. PubMed ID: 20587379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
    Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R
    Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
    Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced neuroendocrine tumors with hepatic metastasis.
    Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
    J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.